Latest Ratings for NARI
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Nov 2021 | SVB Leerink | Maintains | Outperform |
Demystifying Inari Medical: Insights From 6 Analyst Reviews
Where Today's News Shapes Tomorrow
